Published in Urology on January 01, 1995
Prostate cancer: 5. Diagnostic tools for early detection. CMAJ (1998) 1.56
Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study. Br J Gen Pract (2014) 1.44
Prostate cancer: diagnosis and staging. Asian J Androl (2008) 1.21
The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int (2010) 1.04
Prostate mechanical imaging: 3-D image composition and feature calculations. IEEE Trans Med Imaging (2006) 0.96
Transrectal contrast enhanced ultrasound for diagnosis of prostate cancer. World J Urol (2007) 0.79
Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy. Springerplus (2015) 0.78
Does an asymmetric lobe in digital rectal examination include any risk for prostate cancer? results of 1495 biopsies. Int Braz J Urol (2016) 0.75
Nomogram to predict prostate cancer diagnosis on primary transrectal ultrasound-guided prostate biopsy in a contemporary series. Curr Urol (2012) 0.75
Planning primary therapy. Cancer Imaging (2000) 0.75
An audit of prostate-specific antigen and clinical symptoms in general practice. Postgrad Med J (1998) 0.75
No Evidence Supporting the Routine Use of Digital Rectal Examinations in Trauma Patients. Indian J Surg (2015) 0.75
Mechanical Imaging - a Technology for 3-D Visualization and Characterization of Soft Tissue Abnormalities. A Review. Curr Med Imaging Rev (2012) 0.75
Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia. PLoS One (2015) 0.75
Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol (1992) 4.79
Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res (2001) 3.45
Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol (1994) 2.25
Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol (1995) 2.05
Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. Am J Hum Genet (2001) 2.03
Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA (1996) 1.97
A method for dinitrochlorobenzene contact sensitization. A clinicopathological study. N Engl J Med (1972) 1.88
Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol (1994) 1.81
Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol (1998) 1.80
Clinical use of prostate specific antigen in patients with prostate cancer. J Urol (1989) 1.71
Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol (1996) 1.70
A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol (2000) 1.69
Acute normovolemic hemodilution is a cost-effective alternative to preoperative autologous blood donation by patients undergoing radical retropubic prostatectomy. Transfusion (1995) 1.59
Genomewide scan for prostate cancer-aggressiveness loci. Am J Hum Genet (2000) 1.57
Acute normovolemic hemodilution can replace preoperative autologous blood donation as a standard of care for autologous blood procurement in radical prostatectomy. Anesth Analg (1997) 1.56
Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med (2001) 1.55
A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet (2000) 1.51
Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol (2000) 1.50
Acute preoperative hemodilution in patients undergoing radical prostatectomy: a case study analysis of efficacy. Anesth Analg (1994) 1.42
A prospective randomized comparison of three blood conservation strategies for radical prostatectomy. Anesthesiology (1999) 1.41
Antegrade approach to radical retropubic prostatectomy in patients with difficult apical dissection. J Urol (1991) 1.38
Radical surgery for advanced prostate cancer and for radiation failures. J Urol (1992) 1.38
Expectant management and the natural history of localized prostate cancer. J Urol (1994) 1.38
Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. Hum Pathol (2001) 1.37
Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores. J Urol (2000) 1.36
Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer (2000) 1.34
Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer (2000) 1.34
Lymphocyte reactivity in cancer patients: correlation with tumor histology and clinical stage. Cancer (1973) 1.33
Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol (1987) 1.33
The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. Cancer (1997) 1.25
T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol (1993) 1.24
Endocrine therapy for bladder outlet obstruction from carcinoma of the prostate. J Urol (1985) 1.24
Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology (1993) 1.23
Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action. Surg Annu (1990) 1.22
Serum glycoproteins in cancer patients: first report of correlations with in vitro and in vivo parameters of cellular immunity. Cancer (1980) 1.22
Correlation of preoperative lymphocyte reactivity with the clinical course of cancer patients. Surg Gynecol Obstet (1973) 1.21
Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. J Urol (1994) 1.19
Correlations among cutaneous reactivity to DNCB, PHA-induced lymphocyte blastogenesis and peripheral blood E rosettes. Clin Exp Immunol (1975) 1.17
The nature of prostate cancer detected through prostate specific antigen based screening. J Urol (1994) 1.16
Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology (1999) 1.16
Abnormalities of quantitative dinitrochlorobenzene sensitization in cancer patients: correlation with tumor stage and histology. Cancer (1973) 1.16
Quantitative dinitrochlorobenzene contact sensitization in a normal population. Clin Exp Immunol (1972) 1.15
Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res (2001) 1.13
Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology (1996) 1.12
Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol (1997) 1.12
Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol (1987) 1.10
Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol (1994) 1.10
Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology (2000) 1.10
Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol (1998) 1.09
Xanthogranulomatous pyelonephritis masquerading as occult malignancy. Urology (1978) 1.08
Identification and fine mapping of a region showing a high frequency of allelic imbalance on chromosome 16q23.2 that corresponds to a prostate cancer susceptibility locus. Cancer Res (2000) 1.06
Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol (1987) 1.04
Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. J Urol (1997) 1.04
gamma-Interferon induced by S. aureus protein A augments natural killing and ADCC. Nature (1981) 1.00
Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification. Prostate Cancer Prostatic Dis (2006) 1.00
Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. J Urol (1997) 0.99
Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer (2000) 0.99
Proceedings: Cellular immunity in cured cancer patients. Cancer (1974) 0.99
Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol (1994) 0.99
Prostatic cancer, acid phosphatase, creatine kinase-BB and race: a prospective study. J Urol (1982) 0.97
Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology (1997) 0.97
Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. J Urol (1999) 0.97
Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guérin. Cancer Res (1984) 0.96
Production of macrophage activation factor by a T-cell hybridoma. Cell Immunol (1982) 0.95
Interferon induction and augmentation of natural-killer activity by Staphylococcus protein A. Cell Immunol (1981) 0.95
Replication linkage study for prostate cancer susceptibility genes. Prostate (2000) 0.95
Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol (1986) 0.94
Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J Urol (2001) 0.94
Occurrence of hernia of Morgagni with filial cervical lung hernia: a hereditary defect of the cervical mesenchyme? Chest (1972) 0.93
Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol (1988) 0.93
Early complications of contemporary anatomical radical retropubic prostatectomy. J Urol (1994) 0.93
Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J Urol (1996) 0.93
An isolated plexiform neurofibroma of the bladder. J Urol (1985) 0.93
High resolution sonography in diagnosing testicular neoplasms: clinical significance of false positive scans. J Urol (1986) 0.92
Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology (1998) 0.92
Emphysematous pyelonephritis: successful management by percutaneous drainage. J Urol (1986) 0.92
Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. J Urol (1992) 0.92
Efficacy of first-generation Cavermap to verify location and function of cavernous nerves during radical prostatectomy: a multi-institutional evaluation by experienced surgeons. Urology (2001) 0.91
Racial differences in a prostate cancer screening study. J Urol (1996) 0.91
Grading errors in prostatic needle biopsies: relation to the accuracy of tumor grade in predicting pelvic lymph node metastases. J Urol (1982) 0.90
Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors. J Urol (1988) 0.90
Suppression of cellular immunity by anesthesia and operation. J Surg Res (1977) 0.89
Adenomatous polyps of the prostatic urethra: a cause of hematospermia. J Urol (1980) 0.89
Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol (1992) 0.89
T-cell hybridoma production of macrophage activation factor (MAF) I. Separation of MAF from interferon gamma. J Reticuloendothel Soc (1982) 0.89
Long-term follow-up of men undergoing modified inguinal lymphadenectomy for carcinoma of the penis. Br J Urol (1997) 0.88
Correlation of immune reactivity and clinical status in cancer. Ann Clin Lab Sci (1974) 0.88
Screening for prostate cancer: enthusiasm. Urology (1993) 0.88
Role of lymphadenectomy in carcinoma of the penis. Urol Clin North Am (1980) 0.88
Familial aspects of prostate cancer: a case control study. J Urol (1995) 0.88
Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol (1995) 0.88
Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria. Cancer Res (1990) 0.87
Comparison of different serum prostate specific antigen measures for early prostate cancer detection. Cancer (1994) 0.87
Practical utility of specific red cell adherence test in bladder cancer. Urology (1981) 0.86
Effect of mini-dose heparin on lymphocele formation following extraperitoneal pelvic lymphadenectomy. J Urol (1980) 0.86
Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin. J Urol (1986) 0.86
Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer. Clin Immunol Immunopathol (1986) 0.86